Shanghai Bioxin Biotechnology Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 54

Employees

  • Stock Symbol
  • 02185

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.22
  • (As of Friday Closing)

Shanghai Bioxin Biotechnology General Information

Description

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 59 Kaiqing Road, Pudong New Area
  • 4th Floor, Building 7
  • Shanghai, 201201
  • China
+86 021
Primary Industry
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • No. 59 Kaiqing Road, Pudong New Area
  • 4th Floor, Building 7
  • Shanghai, 201201
  • China
+86 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shanghai Bioxin Biotechnology Stock Performance

As of 07-Feb-2025, Shanghai Bioxin Biotechnology’s stock price is $0.22. Its current market cap is $53.5M with 243M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.22 $0.22 $0.16 - $0.41 $53.5M 243M 24.7K -$0.07

Shanghai Bioxin Biotechnology Financials Summary

As of 30-Jun-2024, Shanghai Bioxin Biotechnology has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 11,536 62,172 89,415 775,698
Revenue 0 0 0 0
EBITDA (15,555) (24,154) (31,637) (61,464)
Net Income (16,055) (24,862) (30,327) (55,977)
Total Assets 107,840 115,382 142,264 174,914
Total Debt 136 249 2,624 3,521
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shanghai Bioxin Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shanghai Bioxin Biotechnology‘s full profile, request access.

Request a free trial

Shanghai Bioxin Biotechnology Patents

Shanghai Bioxin Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240226011-A1 Core-shell micelle microsphere, and preparation method therefor and use thereof Pending 28-Dec-2022
JP-2025503347-A Core-shell structured micellar microspheres and preparation method and use thereof Pending 28-Dec-2022
US-20240226387-A1 Drug coating for expandable balloon catheter and preparation method therefor Pending 22-Dec-2022
JP-2025501803-A Drug coating for expandable balloon catheters and method for preparing same - patents.com Pending 22-Dec-2022
US-20240226509-A1 Drug balloon catheter capable of controlling drug release and use thereof Pending 19-Dec-2022 A61L29/085
To view Shanghai Bioxin Biotechnology’s complete patent history, request access »

Shanghai Bioxin Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shanghai Bioxin Biotechnology Investments & Acquisitions (2)

Shanghai Bioxin Biotechnology’s most recent deal was a Early Stage VC with Xinzhi Medical for . The deal was made on 22-Jun-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xinzhi Medical 22-Jun-2022 Early Stage VC Therapeutic Devices
Angio Care China 23-Sep-2020 Merger/Acquisition Biotechnology
To view Shanghai Bioxin Biotechnology’s complete investments and acquisitions history, request access »

Shanghai Bioxin Biotechnology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Shanghai Bioxin Biotechnology’s complete esg history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Angio Care China Shanghai, China 2011

Shanghai Bioxin Biotechnology FAQs

  • When was Shanghai Bioxin Biotechnology founded?

    Shanghai Bioxin Biotechnology was founded in 2014.

  • Where is Shanghai Bioxin Biotechnology headquartered?

    Shanghai Bioxin Biotechnology is headquartered in Shanghai, China.

  • What is the size of Shanghai Bioxin Biotechnology?

    Shanghai Bioxin Biotechnology has 54 total employees.

  • What industry is Shanghai Bioxin Biotechnology in?

    Shanghai Bioxin Biotechnology’s primary industry is Biotechnology.

  • Is Shanghai Bioxin Biotechnology a private or public company?

    Shanghai Bioxin Biotechnology is a Public company.

  • What is Shanghai Bioxin Biotechnology’s stock symbol?

    The ticker symbol for Shanghai Bioxin Biotechnology is 02185.

  • What is the current stock price of Shanghai Bioxin Biotechnology?

    As of 07-Feb-2025 the stock price of Shanghai Bioxin Biotechnology is $0.22.

  • What is the current market cap of Shanghai Bioxin Biotechnology?

    The current market capitalization of Shanghai Bioxin Biotechnology is $53.5M.

  • What is Shanghai Bioxin Biotechnology’s annual earnings per share (EPS)?

    Shanghai Bioxin Biotechnology’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »